Evaluation of: Tsubochi H, Nobuyuki S, Hiyama M et al.: Combined analysis of
cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann. Thorac …

BACKGROUND Cyclooxygenase (Cox) is the main target enzyme for the nonsteroidal
antiinflammatory drugs that have been shown to suppress carcinogenesis in both …

Context.—Previous studies report that increased expression of cyclooxygenase 2 (COX-2)
correlates with poor clinical outcome in several malignancies, including non–small cell lung …

Preclinical studies suggest that cyclooxygenase (COX)-2 may be involved in the molecular
pathogenesis of some types of lung cancer. Most of the available studies point to its …

Lung cancer is the leading cause of cancer death in the United States. Although the low 5-
year survival rate (under 15%) has changed minimally in the last 25 years, new agents and …

Evidence is accumulating to suggest that the inducible isoenzyme of cyclooxygenase (COX)-
2 is up-regulated in human cancers and epidemiological studies indicate that COX inhibitors …

Abstract Cyclooxygenase-2 (COX-2), the enzyme that converts arachidonic acid to
prostaglandins, is overexpressed in a variety of different tumors, including those of the colon …

COX is the key enzyme in the conversion of arachidonic acid to prostanoids, potent bioactive
lipid derivatives that participate in normal growth responses and in aberrant cellular growth …

BACKGROUND: Cyclooxygenase-2 (COX-2) is known to play a role in carcinogenesis and
tumor progression. The aim of this study was to evaluate the relationship between COX-2 …

BACKGROUND: We investigated the prognostic value of cyclooxygenase-2 (COX-2) for
survival of patients with non-small cell lung cancer (NSCLC). METHODS: We performed a …